Developing therapeutic monoclonal antibodies at pandemic pace
Open Access
- 21 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 38 (5), 540-545
- https://doi.org/10.1038/s41587-020-0512-5
Abstract
The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.Keywords
This publication has 24 references indexed in Scilit:
- Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infectionScience, 2016
- A Roadmap for the Implementation of Continued Process VerificationPDA Journal of Pharmaceutical Science and Technology, 2016
- Perfusion seed cultures improve biopharmaceutical fed‐batch production capacity and product qualityBiotechnology Progress, 2014
- A novel approach to achieving modular retrovirus clearance for a parvovirus filterBiotechnology Progress, 2013
- A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A HemagglutininsScience, 2011
- Weak partitioning chromatography for anion exchange purification of monoclonal antibodiesBiotechnology & Bioengineering, 2008
- High‐throughput screening of chromatographic separations: I. Method development and column modelingBiotechnology & Bioengineering, 2008
- Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit OperationsBiotechnology Progress, 2007
- Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesProceedings of the National Academy of Sciences of the United States of America, 2007
- Building biomanufacturing capacity—the chapter and verseNature Biotechnology, 2006